



Szükséges-e nagyobb figyelmet szentelnünk a segédanyagoknak?

- gyógyszerek és tápszerek segédanyagai, mint potenciális allergének



Dr. Haraga Viktória

**SZTE Szent-Györgyi Albert Klinikai Központ
Központi Gyógyszertár, Gyermekgyógyászati Klinika**

**Magyar Mesterséges Táplálási Társaság
2022. évi Kongresszusa
Visegrád, 2022. október 22.**



Segédanyag fogalma

- Segédanyag a gyógyszernek a hatóanyagtól és a csomagolóanyagtól eltérő bármely összetevője (2005. évi XCV. törvény -Gyógyszer tv.)
- Segédanyagnak nevezünk -a hatóanyag(ok)on kívül- minden olyan összetevőt, amelyet a gyógyszerkészítmény tartalmaz vagy amelyet előállításához felhasználtak. A segédanyag lehet: a hatóanyag hordozója (vivőanyag vagy készítményalap) vagy a hordozó egyik összetevője, és alkalmazhatják azzal a céllal, hogy befolyásolja a termék **stabilitását**, **biofarmáciai profilját**, **küllemét** és **felhasználhatóságát** a beteg számára, továbbá megkönnyítse a termék **előállítását**. Egy gyógyszerkészítmény általában többféle segédanyagot tartalmaz (Ph. Hg. VIII.)



Segédanyag alkalmazásával összefüggő kockázatok

- Több ezer segédanyag, sokszor 10 fajta egy gyógyszerkészítményben
- Segédanyagot tartalmazó gyógyszer terápiás területe, gyermekgyógyászati alkalmazás, generikumok
- Segédanyag aránya, mennyisége (napi max. dózisban)
- Segédanyaggal szembeni intolerancia, mellékhatások, túlérzékenység, toxicitás
- Segédanyaggal bevitt szennyezettség (pl. mikrobiológiai, gyártásból származó komponensek, keresztszennyeződések)
- Hamisított segédanyagok
- Új segédanyagok iránti igények, multifunkcionális segédanyagok, korlátozott biztonsági adatok




Leggyakrabban problémát okozó segédanyagok

- Aszpartám
- Azofestékek
- Benzalkónium-klorid
- Benzoésav / benzoátok
- **Benzil-alkohol**
- **Bórsav /borátok**
- Búzakeményítő (glutén)
- **Ciklodextrinek**
- Dextránok
- **Etanol**
- Fenilalanin
- Foszfátok
- Fruktóz, galaktóz, szorbit
- Glicerín
- Gyapjúviasz (lanolin)
- Illatanyagok
- Karboxi-metil-cellulóz
- Laktóz
- **Makrogolok (polietilén-glikol)**
- Mogyoróolaj
- Nátrium-lauril-szulfát
- Parahidroxibenzoátok
- Perubalzsam
- Poliszorbátok (PS 80, PS 20)
- Povidon
- Prolin
- **Propilén-glikol**
- Szerves higanyvegyületek
- Szezámolaj
- Szójaolaj
- Xilit
- Zselatin

Benzil-alkohol

Benzyl alcohol	09/10/2017	Oral, parenteral	Zero	<p>Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called "gaspings syndrome") in young children.</p> <p>Do not give to your newborn baby (up to 4 weeks old), unless recommended by your doctor.</p>	<p>Intravenous administration of benzyl alcohol has been associated with serious adverse events and death in neonates ("gaspings syndrome"). The minimum amount of benzyl alcohol at which toxicity may occur is not known.</p> <p>Warning in section 4.4 in the SmPC should be given if used in neonates.</p>
Benzyl alcohol	09/10/2017	Oral, parenteral	Zero	<p>Do not use for more than a week in young children (less than 3 years old), unless advised by your doctor or pharmacist.</p>	<p>Increased risk due to accumulation in young children.</p>
Benzyl alcohol	09/10/2017	Oral, parenteral	Zero	<p>Ask your doctor or pharmacist for advice if you are pregnant or breast-feeding. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called "metabolic acidosis").</p>	
Benzyl alcohol	09/10/2017	Oral, parenteral	Zero	<p>Ask your doctor or pharmacist for advice if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called "metabolic acidosis").</p>	<p>High volumes should be used with caution and only if necessary, especially in subjects with liver or kidney impairment because of the risk of accumulation and toxicity (metabolic acidosis).</p>
Benzyl alcohol	09/10/2017	Topical	Zero	<p>Benzyl alcohol may cause mild local irritation.</p>	

Felh.: tartósító tulajdonságai miatt segédanyagként, oldódást elősegítő anyagként
(pl.: *Clindamycin inj.*, *Cordarone inj.*, *Diazepam desitin*, *Heparibene Na inj.*, *Synacthen depot inj.*, *Ferrlecit inj.*)



Etanol

Ethanol

22/11/2019

Oral
Parenteral
Inhalation

15 mg/kg
per dose

This medicine contains x mg of alcohol (ethanol) in each <dosage unit> <unit volume> <which is equivalent to x mg/<weight><volume>><(y% w/<w><v>>>. The amount in <dose><volume> of this medicine is equivalent to A ml beer or B ml wine.

The amount of alcohol in this medicine is not likely to have an effect in adults and adolescents, and its effects in children are not likely to be noticeable. It may have some effects in younger children, for example feeling sleepy.

The alcohol in this medicine may alter the effects of other medicines. Talk to your doctor or pharmacist if you are taking other medicines.

If you are pregnant or breast-feeding, talk to your doctor or pharmacist before taking this medicine.

If you are addicted to alcohol, talk to your doctor or pharmacist before taking this medicine.

To calculate the equivalent volume of beer and wine, assume the ethanol content of beer to be 5% v/v (alcohol by volume, ABV), which is equivalent to 4% w/v, and of wine to be 12.5% v/v or 10% w/v (the specific gravity of ethanol has been approximated as 0.8).

Where relevant, the interactions of ethanol should be stated in the SmPC (section 4.5).

Suggestion for information in the SmPC:

A dose of (select maximum dose) of this medicine administered to (a child A years of age and weighing B kg or an adult weighing 70 kg) would result in exposure to C mg/kg of ethanol which may cause a rise in blood alcohol concentration (BAC) of about D mg/100 ml (see Appendix 1 of report EMA/CHMP/43486/2018).

For comparison, for an adult drinking a glass of wine or 500 ml of beer, the BAC is likely to be about 50 mg/100 ml.

Co-administration with medicines containing e.g. propylene glycol or ethanol may lead to accumulation of ethanol and induce adverse effects, in particular in young children with low or immature metabolic capacity.

When a dose is given over prolonged period (e.g. by slow infusion over several hours), the rise in BAC will be less and the effects of ethanol may be

Felh.: oldószerként a gyógyszer oldhatóságának javítására, extrakciós oldószerként gyógynövénykészítményekben, bakteriosztatikus, baktericid, gombaölő és virucid hatású (pl.: *Bactrimel / Cotrim inj.*, *Epanutin inj.*, *Prostin inj.*, *Simdax inj.*)

Propilén-glikol

Propylene glycol (E 1520) and esters of propylene glycol	09/10/2017	All	1 mg/kg/day	This medicine contains x mg propylene glycol in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>.	
Propylene glycol (E 1520) and esters of propylene glycol	09/10/2017	Oral, parenteral	1 mg/kg/day	If your baby is less than 4 weeks old, talk to your doctor or pharmacist before giving them this medicine, in particular if the baby is given other medicines that contain propylene glycol or alcohol.	Co-administration with any substrate for alcohol dehydrogenase such as ethanol may induce serious adverse effects in neonates.
Propylene glycol (E 1520) and esters of propylene glycol	09/10/2017	Oral, parenteral	50 mg/kg/day	If your child is less than 5 years old, talk to your doctor or pharmacist before giving them this medicine, in particular if they use other medicines that contain propylene glycol or alcohol.	Co-administration with any substrate for alcohol dehydrogenase such as ethanol may induce adverse effects in children less than 5 years old.
Propylene glycol (E 1520) and esters of propylene glycol	09/10/2017	Oral, parenteral	50 mg/kg/day	If you are pregnant or breast-feeding, do not take this medicine unless recommended by your doctor. Your doctor may carry out extra checks while you are taking this medicine.	While propylene glycol has not been shown to cause reproductive or developmental toxicity in animals or humans, it may reach the foetus and was found in milk. As a consequence, administration of propylene glycol to pregnant or lactating patients should be considered on a case by case basis.
Propylene glycol (E 1520) and esters of propylene glycol	09/10/2017	Oral, parenteral	50 mg/kg/day	If you suffer from a liver or kidney disease, do not take this medicine unless recommended by your doctor. Your doctor may carry out extra checks while you are taking this medicine.	Medical monitoring is required in patients with impaired renal or hepatic functions because various adverse events attributed to propylene glycol have been reported such as renal dysfunction (acute tubular necrosis), acute renal failure and liver dysfunction.

Felh.:bőrgyógyászati készítményekben nedvesítőszerként, oldatokban tartósítószerként, aeroszolokban parenterális készítményekben és oldatokban segédoldószerként
(pl.: Dexamethason-ratiopharm inj., Bactrimel inj., Epanutin inj.)

Ciklodextrin

<p>Cyclodextrins</p> <p>e.g.: Alfadex Betadex (E 459) γ-cyclodextrin Sulfobutyl-ether-β-cyclodextrin (SBE-β-CD) Hydroxypropyl betadex Randomly methylated β-cyclodextrin (RM-β-CD)</p>	09/10/2017	All	20 mg/kg/day	<p>This medicine contains x mg cyclodextrin(s) in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>.</p> <p>Do not use in children less than 2 years old unless recommended by your doctor.</p>	<p>Cyclodextrins (CDs) are excipients which can influence the properties (such as toxicity or skin penetration) of the active substance and other medicines. Safety aspects of CDs have been considered during the development and safety assessment of the drug product, and are clearly stated in the SmPC.</p> <p>There is insufficient information on the effects of CDs in children < 2 years old. Therefore, a case by case judgement should be made regarding the risk/benefit for the patient.</p> <p>Based on animal studies and human experience, harmful effects of CDs are not to be expected at doses below 20 mg/kg/day.</p>
<p>Cyclodextrins</p> <p>e.g.: Alfadex Betadex (E 459) γ-cyclodextrin Sulfobutyl-ether-β-cyclodextrin (SBE-β-CD) Hydroxypropyl betadex Randomly methylated β-cyclodextrin (RM-β-CD)</p>	09/10/2017	Oral	200 mg/kg/day	<p>Cyclodextrins may cause digestive problems such as diarrhoea.</p>	<p>At high doses cyclodextrins can cause reversible diarrhoea and cecal enlargement in animals.</p>
<p>Cyclodextrins</p> <p>e.g.: Alfadex Betadex (E 459) γ-cyclodextrin Sulfobutyl-ether-β-cyclodextrin (SBE-β-CD) Hydroxypropyl betadex Randomly methylated β-cyclodextrin (RM-β-CD)</p>	09/10/2017	Parenteral	200 mg/kg/day and use for > 2 weeks	<p>If you have a kidney disease, talk to your doctor before you receive this medicine.</p>	<p>In children less than 2 years, the lower glomerular function may protect against renal toxicity, but can lead to higher blood levels of cyclodextrins.</p> <p>In patients with moderate to severe renal dysfunction accumulation of cyclodextrins may occur.</p>

Felh: vízdékonyság fokozására, gyógyszerek biológiai hozzáférhetőségének javítására tablettákban, parenterális oldatokban, orrsprayben és szemcseppekben
(pl.: Vorikonazol inf., Veklury inf., sugammadex, Flector Rapiven inj.)



Bórsav / borát

Name	Route of Administration	Threshold	Information for the Package Leaflet	Comments										
Boric acid (and borates)	All routes of administration	1 mg B/day*	Do not give to a child less than 2 years old as this medicine contains boron and may impair fertility in the future.	<p>* 1 mg B (Boron) = 5.7 mg boric acid</p> <p>See Q&A document [link to be inserted] for further calculations.</p> <p>Amount of boron per age group which may impair fertility if exceeded:</p> <table border="1"> <thead> <tr> <th>Age</th> <th>Safety limit</th> </tr> </thead> <tbody> <tr> <td>< 2 years</td> <td>1mg B/day</td> </tr> <tr> <td>< 12 years</td> <td>3 mg B/day</td> </tr> <tr> <td>< 18 years**</td> <td>7 mg B/day</td> </tr> <tr> <td>≥ 18 years**</td> <td>10 mg B/day</td> </tr> </tbody> </table> <p>** This amount may also cause harm to the unborn child.</p>	Age	Safety limit	< 2 years	1mg B/day	< 12 years	3 mg B/day	< 18 years**	7 mg B/day	≥ 18 years**	10 mg B/day
		Age	Safety limit											
		< 2 years	1mg B/day											
< 12 years	3 mg B/day													
< 18 years**	7 mg B/day													
≥ 18 years**	10 mg B/day													
3 mg B/day*	Do not give to a child less than 12 years old as this medicine contains boron and may impair fertility in the future.													
7 mg B/day*	<p>Do not give to a child less than 18 years old as this medicine contains boron and may impair fertility in the future.</p> <p>If you are pregnant, talk to your doctor before taking this medicine as it contains boron which may be harmful to your baby.</p>													

Further scientific background is available in the report entitled 'Boric acid and borates used as excipients' [3].

Felh.: antimikrobiális tartósítószer, pufferanyag a pH szabályozására.
Elsősorban magisztrális készítményekben, szemcseppekben



Élelmiszerekből előállított segédanyagok

- Tojás (tojás fehérje, ovalbumin, lecitin, foszfolipidek)
 - influenza vakcina, probiotikumok, propofol, zsíremulziók, TPN
- Hal
 - Protamin -inzulinok, halolaj, multivitaminok
- Zselatin
 - Lágy zselatin kapszulák, plazma expanderek, varicella vakcina, vérzéscsillapító szivacs
- Tej (kazein, tejfehérje, laktóz)
 - probiotikumok, tabletták, kapszulák, porok, inhalációs készítmények
- Mogyoróolaj
 - dimercaptol inj.
- Szezámolaj
 - Haloperidol decanoat inj
- Szójaolaj
 - propofol, progeszteron kapsz., liposzómás amphotericin B
- Kagyló (glükózamin)
- Búzakeményítő (glutén)

ISOPRINOSINE 500 MG TABLETTA - LAKTÓZ, BÚZAKEMÉNYÍTŐ, BENZOÁT TARTALOM

Megnevezés	Tartalom	Mennyiség
Laktóz	Nincs	
Búzakeményítő	Van	
Benzoát	Nincs	



Segédanyag szennyeződés

W.M. Snellings et al. / Regulatory Toxicology and Pharmacology 87 (2017) S1–S20



S3

Table 1
Summary major diethylene glycol mass poisoning incidences.

Outbreak Year	Outbreak Country	Implicated Medication	Route of Exposure	Reference
1937	USA	Elixir of Sulfanilamide	oral	Calvery and Klumpp (1939)
1969	South Africa	Sedative	oral	Bowie and McKenzie (1972)
1986	India	Glycerin	unknown	Patel (1988)
1990	Nigeria	Acetaminophen	oral	
1990	Bangladesh	Acetaminophen	oral	
1992	Argentina	Propolis syrup	oral	
1995	Haiti	Acetaminophen	oral	
1998	India	Cough expectorant	oral	
1998	India	Acetaminophen	oral	
2006	Panama	Cough syrup	oral	
2008	Nigeria	Analgesic	oral	



Home / News / Medical Product Alert N°6/2022: Substandard (contaminated) paediatric medicines

Medical Product Alert N°6/2022: Substandard (contaminated) paediatric medicines

Substandard (contaminated) paediatric medicines identified in WHO region of Africa

5 October 2022 | Medical product alert | Geneva | Reading time: 2 min | 405 words

Alert Summary

This WHO Medical Product Alert refers to four substandard products, identified in The Gambia and reported to WHO in September 2022. Substandard medical products are products that fail to meet either their quality standards or specifications and are, therefore "out of specification"[1].

The four products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup. The stated manufacturer of these products is Maiden Pharmaceuticals Limited (Malyasia), who has stated manufacturer has not provided guarantees to WHO on the safety and quality of these



WARNING OVER COUGH SYRUPS
6th October, 2022

Manufacturer: Maiden Pharmaceuticals Limited (Malyasia, India)
Contain unacceptable diethylene glycol and ethylene glycol which are toxic to humans when consumed & can prove fatal

Products have been identified in The Gambia, but may have been distributed, through informal markets, to other countries or regions.

Source: World Health Organization

www.citizen.digital

analysis of samples of each of the four products confirms that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants. To date, these four products have been identified in The Gambia and have been distributed, through informal markets, to other countries or regions.
https://www.who.int/teams/regulation-prequalification/incidents-and-SFI/background/definitions

diethylene glycol and ethylene glycol are toxic to humans when consumed and can prove fatal

may include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state, and respiratory distress, which may lead to death.

These products should be considered unsafe until they can be analyzed by the relevant National Reference Laboratories.

The products referenced in this alert are unsafe and their use, especially in children, may result in death.

Recommendations to regulatory authorities and the public

Regulatory authorities should detect and remove these substandard products from circulation to prevent harm to patients.

Increased surveillance and diligence within the supply chains of countries and regions likely to be affected by these products. Increased surveillance of the informal/unregulated market is also advised.

These products may be prepared and obtained from unlicensed/unlicensed suppliers. The products' authenticity and quality cannot be guaranteed.

Adapted from Sosa et al. (2014).



Home / Disease Outbreak News / Item / Melamine-contaminated powdered infant formula in China - update 2

2008 - China

29 September 2008

29 September 2008 - More than 54,000 infants and young children have sought medical treatment in relation to the melamine-contaminated dairy products in China, causing kidney stone. Three deaths among infants have been confirmed, more than 13,000 infants are in hospital. Kidney stones in infants are normally very rare.

The World Health Organization has published "Melamine and Cyanuric acid: Toxicity, Preliminary Risk Assessment and Guidance on Levels in Food". This preliminary guidance was developed to assist national authorities in the decision-making process on deciding possible health concern of melamine levels in food.

This preliminary guidance is proposed as a first pragmatic approach until more data become available which would allow a more detailed assessment.

Esetismertetés -anti-PEG Abs

- 2016. 6 éves kisfiú -haemophilia diagnózis, VIII-as faktor szubsztitúció
- 2020-tól rendszeres faktorpótlás, pk alapján megfelelő faktorszint
- 2021.07.19. hosszított felezési idejű készítményre váltás → PEG-al konjugált VIII-as faktor → tesztdózis utáni pk mérés nem megfelelő faktorszintet mutatott
- PEG ellenes antitestek kimutatása (készítmény elleni neutralizáló AT jelenléte kizárható)
- 2021.08.23. PEG –et nem tartalmazó faktor készítmény beállítása után megfelelő faktorszint

2021.07.08. COVID-19 mRNS-vakcina

- anti-PEG antitestek → felgyorsult gyógyszerkiürülés, csökkent klinikai hatékonyság, súlyos túlérzékenységi reakciók.
- SARS-CoV-2 RNS vakcinák széles körben elterjedt alkalmazása, gyakori emlékeztető oltások hatása

Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine

Yi Ju,[†] Wen Shi Lee, Emily H. Pilkington, Hannah G. Kelly, Shiyao Li, Kevin J. Selva, Kathleen M. Wragg, Kanta Subbarao, Thi H. O. Nguyen, Louise C. Rowntree, Lilith F. Allen, Katherine Bond, Deborah A. Williamson, Nghia P. Truong, Magdalena Plebanski, Katherine Kedzierska, Siddhartha Mahanty, Amy W. Chung, Frank Caruso, Adam K. Wheatley, Jennifer A. Juno, and Stephen J. Kent[†]

Segédanyag alkalmazásával összefüggő kockázatok csökkentésének lehetőségei



- Gyógyszermellékhatás, hatáscsökkenés → gondoljunk a segédanyagokra is
- Segédanyag toxicitás, allergia megelőzése, felismerése

klinikai gyógyszerész szerepe

– gyógyszer összetételének pontos ismerete, gyógyszeres anamnézis, 9M, off-label indikációk

- *Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668)*
- *European Paediatric Formulation Initiative (EuPFI) - STEP (Safety and Toxicity of Excipients for Paediatrics) adatbázis*
Pediatric Excipient Risk Assessment (PERA)
- *Az Európai Parlament és Tanács 2001/83/EK irányelve (2001. november 6.) az emberi felhasználásra szánt gyógyszerek közösségi kódexéről*